Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi
Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi
复制标题
DOI：
10.1016/j.actatropica.2007.04.006
复制
发表时间：
2007-05-01
期刊：
影响因子：
2.7
通讯作者：
Ward, Stephen
中科院分区：
文献类型：
--
作者：
Nkhoma, Standwell;Molyneux, Malcolm;Ward, Stephen
我们评估了来自马拉维三个地理不同地点的178例恶性疟原虫感染中与氯喹(CQ)和磺胺二甲基乙胺(SP)耐药性相关的点突变的存在。我们确认，CQ耐药突变在马拉维现在很少见，在来自三个研究地点中的两个地点的感染中可以检测到非常低的频率(2-4%)。我们还表明，来自三个研究地点的超过90%的感染携带一组三个二氢叶酸还原酶(DHFR)和两个二氢翼酸合成酶(DHPs)突变，与SP治疗失败密切相关。在这个简短的交流中，我们介绍了这些分子数据，并讨论了它们对马拉维一线抗疟疾治疗政策的影响。(C)2007 Elsevier B.V.保留所有权利。
We assessed the presence of point mutations associated with resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) in 178 Plasmodium falciparum infections from three geographically distinct sites in Malawi. We confirm that CQ-resistance mutations are now rare in Malawi, being detectable at very low frequencies (2-4%) in infections from two of the three study sites. We also show that over 90% of infections from each of the three study sites carry a set of three dihydrofolate reductase (dhfr) and two dihydropteroate synthase (dhps) mutations strongly associated with SP treatment failure. In this short communication, we present these molecular data and discuss their implications for Malawi's first-line antimalarial treatment policy. (C) 2007 Elsevier B.V. All rights reserved.